StockIQpro
NASDAQ:TCRT

Alaunos Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Alaunos Therapeutics, Inc.'s revenue fell 50.0% in fiscal 2025 to $5,000 while operating margin fell to −84500.0%. Free cash flow was −$3.0M, −59340.0% of revenue, and the diluted share count rose 21.7%.Summary generated from Alaunos Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 31, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$5,000
Revenue growth−50.0%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−84500.0%
Net margin−83520.0%
ROICn/a
Return on equity−198.1%
Debt / equityn/a
Free cash flow−$3.0M
FCF margin−59340.0%
Share count change+21.7%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue03000
Operating income−78−35−34−5−4
Net income−79−38−5−5−4
Free cash flow−65−29−30−5−3

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations